Good piece on the happenings in the sickle cell disease space after the big ASH conference

Comprehensive piece of the primary NASH programs investors need to keep an eye in the quarters and years ahead.

$BOLD becomes the second big acquisition in the biotech space this morning in 8 days (MDCO last week). Who's next? …

Big week for biotech as far as conferences and some trial presentations. Good piece on what to watch for this week.

Quick piece on three key FDA decisions still left in 2019

Does Novartis' buyout of the Medicines Company put Amarin in play?

Good piece on Alnylam's FDA approval yesterday

Interesting piece on what FDA head Gottlieb is now doing with his time and efforts.

Solid article on the rumors around an Amgen/Alexion tie up. …

Good piece on emerging developments in targeting pancreatic cancer. Well worth the read. …